ESMO: Despite survival miss, Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan

0

16.09.2024 23:14

Fiercepharma.com

ESMO: Despite survival miss, Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan aliu Mon, 09/16/2024 - 16:14